BioNTech SE (BNTX) posted a Q4 2025 adjusted net loss of €0.33 per share. Revenue was €907.4M. The German biotechnology company develops and commercializes immunotherapies to treat cancer and infectious diseases.
BioNTech’s portfolio includes multiple clinical-stage oncology candidates, with BNT111 in Phase 2 trials for advanced melanoma and BNT113 in Phase 2 for head and neck squamous cell carcinoma. The company also maintains programs in non-small cell lung cancer and various solid tumors across different trial phases.
A detailed analysis of BioNTech SE’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.